Top in allergy/asthma: FDA needs more data on nasal spray; what patients with asthma want
Click Here to Manage Email Alerts
The FDA asked ARS Pharma for additional testing of its epinephrin nasal spray neffy, which was developed to treat type 1 allergic reactions, before the agency makes a decision regarding the company’s new drug application.
It was the top story in allergy/asthma last week.
Another top story discussed how patients with asthma prioritize short-term improvements — like fewer asthma attacks requiring urgent care — over long-term goals, according to researchers.
Read these and more top stories in allergy/asthma below:
FDA asks ARS Pharma for more testing in epinephrine nasal spray approval process
The FDA has issued a complete response letter to ARS Pharma concerning its new drug application for neffy epinephrine nasal spray, according to a press release from the company. Read more.
Patients prioritize short-term improvements over long-term risks in asthma care
Patients with asthma preferred convenient management options that prioritized decreases in short-term morbidity over long-term goals, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Index indicates global shortcomings in severe asthma care
Individual nation results from the Severe Asthma Index indicate that the disease remains inadequately prioritized around the world, according to an abstract presented at the European Respiratory Society International Congress. Read more.
NY law requires educational materials about anaphylaxis, autoinjectors for teachers
New York Gov. Kathy Hochul has signed legislation that requires the state’s commissioner of health to provide written information on how to recognize anaphylaxis and use epinephrine autoinjectors to the state’s teachers. Read more.
Lack of timely follow-up care common among patients with eosinophilic esophagitis
Adults with eosinophilic esophagitis often failed to return to their specialist for timely follow-up care, according to a letter published in Annals of Allergy, Asthma & Immunology. In a perspective, Amanda Michaud, DMSc, PA-C, AE-C, offered her reaction to the findings. Read more.